Research Perspectives:
From osimertinib to preemptive combinations
PDF | Full Text | How to cite | Press Release
Metrics: PDF 204 views | Full Text 1483 views | ?
Abstract
Mikhail V. Blagosklonny1
1 Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
Correspondence to:
Mikhail V. Blagosklonny, | email: | Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com |
Keywords: lung cancer; NSCLC; EGFR; resistance; afatinib; gefitinib; capmatinib
Received: February 23, 2024 Accepted: March 11, 2024 Published: March 15, 2024
ABSTRACT
Here, I suggest that while first-line osimertinib extends median progression-free survival (PFS) in EGFR-mutant lung cancer compared to first-generation TKIs, it reduces individual PFS in 15–20% of patients compared to first-generation TKIs. Since detecting a single resistant cell before treatment is usually impossible, osimertinib must be used in all patients as a first-line treatment, raising median PFS overall but harming some. The simplest remedy is a preemptive combination (PC) of osimertinib and gefitinib. A comprehensive PC (osimertinib, afatinib/gefitinib, and capmatinib) could dramatically increase PFS for 80% of patients compared to osimertinib alone, without harming anyone. This article also explores PCs for MET-driven lung cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28569